Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About
ANEW Medical Inc is a US-based company operating in Financial Services industry. The company is headquartered in New York City, New York. The company went IPO on 2022-04-29. ANEW Medical, Inc. is a specialty pharmaceutical company. The firm specializes in the development of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. The firm focuses on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer's disease (AD), dementia symptoms and neuromuscular diseases. The firm has exclusive worldwide rights to develop and commercialize product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or s-KL. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease. Its lead gene therapy product candidates are AMI-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and AMI-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease.
Industry: Biological Products, (No Diagnostic Substances) Peers: California First Leasing Corp FlexShopper Inc Future Fintech Group Inc HA Sustainable Infrastructure Capital Inc Sundance Strategies Inc Mill City Ventures III Ltd SHF Holdings Inc Standard Premium Finance Holdings Inc
